GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Cash, Cash Equivalents, Marketable Securities

Antares Pharma (Antares Pharma) Cash, Cash Equivalents, Marketable Securities : $62.2 Mil (As of Mar. 2022)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Cash, Cash Equivalents, Marketable Securities?

Antares Pharma's quarterly cash, cash equivalents, marketable securities increased from Sep. 2021 ($57.37 Mil) to Dec. 2021 ($67.16 Mil) but then stayed the same from Dec. 2021 ($67.16 Mil) to Mar. 2022 ($62.21 Mil).

Antares Pharma's annual cash, cash equivalents, marketable securities increased from Dec. 2019 ($45.72 Mil) to Dec. 2020 ($53.14 Mil) and increased from Dec. 2020 ($53.14 Mil) to Dec. 2021 ($67.16 Mil).


Antares Pharma Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Antares Pharma's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Cash, Cash Equivalents, Marketable Securities Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.56 27.89 45.72 53.14 67.16

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.65 45.13 57.37 67.16 62.21

Antares Pharma Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Antares Pharma  (NAS:ATRS) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Antares Pharma Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447